

Version of Amended Claims With Markings to Show Changes Made:

- 4. (Amended) An isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of:
- (a) a nucleotide sequence that encodes a protein comprising the [an] amino acid sequence of [shown in] SEQ ID NO:2;
- [(b) a nucleotide sequence that encodes of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (d) a nucleotide sequence that encodes a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids; and]
 - (b) a nucleotide sequence consisting of SEQ ID NO:1;
 - (c) a nucleotide sequence consisting of SEQ ID NO:3; and
- (d) r [(e)] a nucleotide sequence that is [the complement of] completely complementary to a nucleotide sequence of (a)-[(d)](c).
- 8. (Amended) A nucleic acid vector comprising a nucleic acid molecule of claim [5] 4.
- 13. (Amended) A method for detecting the presence of a nucleic acid molecule of claim [5] 4 in a sample, said method comprising

contacting the sample with an oligonucleotide comprising at least 20 contiguous



Serial No. 09/778,963

nucleotides that hybridizes to said nucleic acid molecule under stringent conditions, wherein the stringent condition is hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SCC, 0.1% SDS at 50-65°C, and

determining whether the oligonucleotide binds to said nucleic acid molecule in the sample.



Serial No. 09/778,963

REMARKS

By way of the above amendments, claims 1-3, 5-7, 10-12, and 14-23 have been canceled as being redundant or being directed to non-elected subject matter; claims 4, 8 and 13 have been amended; and claims 24-29 have been added. As such, claims 4, 8-9, 13 and 24-29 are presently pending.

Support for the amendments to the claims and the newly added claims can be found at least in the old claims and in Figures 1-3. The amendments to the claims and the newly added claims add no new subject matter and their entry is respectfully requested.

Applicants respectfully assert that the claims are in condition for examination on the merits.

Respectfully submitted,

CELERA GENOMICS

Justin D. Karjal

Reg. No. 43,704

Date: November 5, 2001

Celera Genomics Corporation
45 West Gude Drive, C2-4#20

Rockville, MD 20850 Tel: 240-453-3812

Fax: 240-453-3084

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: NEELAM et al.

Art Unit: 1642

Serial No. 09/778,963

Examiner: K. Canella

Filed: February 8, 2001

Atty. Docket: CL001112

For: ISOLATED HUMAN RAS-LIKE PROTEINS, NUCLEIC ACID MOLECULES ENCODING THESE HUMAN RAS-LIKE PROTEINS, AND USES THEREOF

Statement Regarding Duty Of Disclose Information Material To Patentability Under 37 CFR 1.56 (a) and (b)

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231 By Facsimile

Sir:

This statement is to inform the United States of Patent and Trademark Office that Applicants and their representative have made a good faith effort in searching prior art relating to this invention.

No prior art material to patentability of the present invention has been found. The closest information associated with the invention is disclosed in Figures 1 and 2 in the top BLAST search results. However, this information, by itself or in combination with other information, does not constitute a prima facie case of unpatentability of any of the pending claims. Thus, it does not defeat the novelty of the present invention and the actual underlying references for the top BLAST hits are not being provided.

Respectfully submitted,

CELERA GENOMICS

Date: November 5, 2001

Justin D. Karjala, Reg No. 43,704

Celera Genomics Corporation 45 West Gude Drive, C2-4#20 Rockville, MD 20850

Tel: 240-453-3812 Fax: 240-453-3084